Erlotinib treatment beyond progression in EGFR mutant or patients who have responded to EGFR TKI in stage IIIB/IV NSCLC
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
Price : $35 *
At a glance
- Drugs Erlotinib (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms ETAP
- 31 Aug 2018 Biomarkers information updated
- 26 Apr 2017 Status changed from recruiting to completed.
- 12 Sep 2016 Planned End Date changed from 29 Nov 2016 to 1 May 2017.